bluebird bio Inc (BLUE)
1.365
+0.16
(+13.75%)
USD |
NASDAQ |
Mar 27, 16:00
1.35
-0.02
(-1.10%)
Pre-Market: 09:08
bluebird bio Cash from Financing (TTM): 129.85M for Sept. 30, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
September 30, 2023 | 129.85M |
June 30, 2023 | 176.22M |
March 31, 2023 | 184.70M |
December 31, 2022 | 54.25M |
September 30, 2022 | -119.65M |
June 30, 2022 | -90.10M |
March 31, 2022 | -97.74M |
December 31, 2021 | -93.95M |
September 30, 2021 | 81.49M |
June 30, 2021 | 6.822M |
March 31, 2021 | 549.55M |
December 31, 2020 | 546.72M |
September 30, 2020 | 547.29M |
June 30, 2020 | 550.27M |
March 31, 2020 | 11.93M |
December 31, 2019 | 21.19M |
September 30, 2019 | 21.10M |
June 30, 2019 | 675.72M |
March 31, 2019 | 676.24M |
December 31, 2018 | 737.69M |
September 30, 2018 | 1.324B |
June 30, 2018 | 671.43M |
Date | Value |
---|---|
March 31, 2018 | 1.131B |
December 31, 2017 | 1.076B |
September 30, 2017 | 727.62M |
June 30, 2017 | 723.93M |
March 31, 2017 | 257.77M |
December 31, 2016 | 241.53M |
September 30, 2016 | 2.778M |
June 30, 2016 | 3.348M |
March 31, 2016 | 484.90M |
December 31, 2015 | 486.72M |
September 30, 2015 | 732.01M |
June 30, 2015 | 839.26M |
March 31, 2015 | 360.24M |
December 31, 2014 | 358.45M |
September 30, 2014 | 112.37M |
June 30, 2014 | 0.948M |
March 31, 2014 | 106.69M |
December 31, 2013 | 105.64M |
September 30, 2013 | 105.39M |
June 30, 2013 | 166.43M |
March 31, 2013 | 59.47M |
December 31, 2012 | 59.85M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-119.65M
Minimum
Sep 2022
676.24M
Maximum
Mar 2019
201.68M
Average
81.49M
Median
Sep 2021
Cash from Financing (TTM) Benchmarks
Vertex Pharmaceuticals Inc | -562.20M |
Agenus Inc | 119.87M |
Neurocrine Biosciences Inc | 65.30M |
Motus GI Holdings Inc | 2.214M |
AIM ImmunoTech Inc | 0.338M |